Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
GE HealthCare and Medtronic integrate bkActiv iUS and Stealth AXiS system
GE HealthCare has integrated its bkActiv intraoperative ultrasound (iUS) system with Medtronic's Stealth AXiS surgical navigation system to provide imaging …
-
AllRock Bio begins patient dosing in Phase IIa ROCSTAR trial
AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral pan-rho-associated protein …
-
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the clinical development, regulatory approval, and …
-
MHRA secures $4.8m to expand AI medical device programme
The Medicines and Healthcare products Regulatory Agency (MHRA) has secured a £3.6m ($4.8m) funding increase over three years to expand …
-
Hemispherian begins Phase I/IIa trial of GLIX1 for GBM
Hemispherian has initiated a first-in-human Phase I/IIa trial of its oral small molecule, GLIX1, in patients with recurrent and progressive …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Jeito Capital secures over $1.2bn for new biopharma investments
Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn), …
-
J&J advances PFA portfolio with Varipulse Pro launch in Europe
Johnson & Johnson (J&J) has launched Varipulse Pro in Europe after securing CE Mark approval, strengthening its pulsed field ablation …
-
First patient dosed in CatalYm’s Phase IIb visugromab trial
CatalYm has dosed the first patient in its Phase IIb GDFATHER-HCC-01 clinical trial, assessing visugromab, along with chemoimmunotherapy as a …
-
Halozyme and Vertex sign deal for Hypercon technology
Halozyme Therapeutics' subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former's …
-
Rethinking the microbiology workflow with smarter tools for faster answers and less waste
Microbiology laboratories face competing demands to deliver rapid, accurate results while managing rising caseloads and meeting sustainability and financial goals. …
-
The hidden bottleneck in digital healthcare: Why hospital wireless networks are under pressure in 2026
Healthcare is entering a new era of digital transformation. In the US, competition among leading providers is driving rapid adoption …
-
Stereotaxis launches Synchrony system for cath labs
Stereotaxis has launched the Synchrony system for cath laboratories after receiving 510(k) clearance from the US Food and Drug Administration …
-
Affinia gains Health Canada approval for UPBEAT Phase I/II trial
Affinia Therapeutics has received approval from Health Canada for its clinical trial application (CTA) to begin the UPBEAT Phase I/II …
-
Neurocrine to acquire Soleno in $2.9bn transaction
Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, which represents $2.9bn …
-
Zeto receives FDA clearance for New Wave EEG system
Zeto has received the US Food and Drug Administration (FDA) 510(k) clearance for its New Wave electroencephalogram (EEG) system, marking …
